(Q34721485)

4 August 2017

title

Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension (English)

1 reference

4 August 2017

Zeenat Safdar

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

2 March 2011

1 reference

Vascular Health and Risk Management

4 August 2017

published in

1 reference

4 August 2017

volume

7

1 reference

4 August 2017

page(s)

119-124

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

4 August 2017

copyright license

start time

1 March 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Targeted oral therapies in the treatment of pulmonary arterial hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064451

Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064451

A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064451

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064451

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064451

Sitaxsentan therapy for pulmonary arterial hypertension

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064451

Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064451

Pathology and pathophysiology of primary pulmonary hypertension

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064451

Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064451

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064451

Ambrisentan therapy for pulmonary arterial hypertension

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3064451

Endothelin antagonists: substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21468170

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bosentan therapy for pulmonary arterial hypertension

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21468170

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Endothelin receptor antagonists

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21468170

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2147/VHRM.S15026

1 reference

4 August 2017

1 reference

4 August 2017

1 reference